moxifloxacin

(redirected from Vigamox)
Also found in: Medical.

mox·i·flox·a·cin

 (mŏk′sĭ-flŏk′sə-sĭn)
n.
An antibiotic drug of the fluoroquinolone class, C21H24FN3O4, used primarily to treat respiratory, sinus, and skin infections.

[m(eth)- + alteration of oxy- + -floxacin, fluoroquinolone suff.; see ciprofloxacin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

moxifloxacin

n moxifloxacino, moxifloxacina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
All patients were treated with topical antibiotics (Moxifloxacin 0.5% - Vigamox, Alcon, Belgium), 24 hours prior to IVTA and continued for three days, post-injection.
Topical vigamox (moxifloxacin 0.5%) qid, cyclopen (cyclopentolate sodium 1%) tds and pred forte (prednisolone acetate 1%) eye drops were advised.
After the injection, an ophthalmic solution of 0.5% moxifloxacin (Vigamox; Alcon Laboratories, Inc., Fort Worth, Texas, USA) was administered 5 times a day for 1 week.
Ten anti-infectives are available for topical treatment of eye infections (systemic concentrations if known): besifloxacin (Besivance) (0.43 ng/mL), ciprofloxacin (less than 2.5 ng/mL), gentamicin, gatifloxacin (Zymaxid) (less than 5 ng/mL), levofloxacin (Iquix) (10.9 ng/mL), moxifloxacin (Vigamox) (2.7 ng/mL), ofloxacin (1.9 ng/ mL), sulfacetamide (Isopto Cetamide), and tobramycin.
However, given the findings and lack of associated symptoms, a diagnosis of sterile peripheral infiltrates was made; moxifloxacin 0.5% (Vigamox) and prednisolone acetate 1% (Pred Forte) were increased from q.i.d.
(There is also allergen or irritant conjunctivitis.) Bacterial conjunctivitis is relatively easy to treat with antibiotic eye drops, moxifloxacin (sold under the brand name Vigamox).
The trials compared besifloxacin with a vehicle suspension in two studies and with moxifloxacin HCl ophthalmic solution 0.5% (Vigamox) in the third study.
The trials compared besifloxacin with a vehicle suspension in two studies and to moxifloxacin HC1 ophthalmic solution 0.5% (Vigamox) in the third study.
Before the surgery, tetracaine hydrochloride 0.5% ophthalmic solution (Bausch & Lomb, Minims) and moxifloxacin 0.5% (Vigamox, Alcon Co.) drops were instilled 3 times within a 5-minute interval.
Both groups were administered the same postoperative medication regimen; they were given Moxifloxacin 0.5% eye drops (Vigamox, Alcon) four times a day for two week, topical loteprednol (Lotemax ophthalmic suspension, Bausch and Lomb) 4 times a day in tapering doses for 4 weeks, and topical artificial tear supplements four times a day for one month.
Intracameral moxifloxacin 0.5% (0.1ml Vigamox; Alcon Labs) was given.